Buyside wrestles with OTC derivatives valuation

© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Buyside wrestles with OTC derivatives valuation

Jeweler's loupe
Tinichan - Fotolia

Buyside participants, in particular insurance firms and pension schemes, have not adequately invested in risk management infrastructure and are not pricing their derivatives exposures or collateral charges effectively in light of new rules and accounting standards.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login
  • 4,000 annual insights
  • 700+ notes and long-form analyses
  • 4 capital markets databases
  • Daily newsletters across markets and asset classes
  • 2 weekly podcasts

Related articles

Gift this article